Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02276170 · ClinicalTrials.gov registry record

Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

A clinical trial, sponsored by Stanford University.

Terminated
Registry status
9
Enrollment target

NCT02276170: Clinical Trial study, sponsored by Stanford University.

NCT02276170 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02276170 was terminated before completion, sponsored by Stanford University.

TERMINATED
Registry status
9 participants
Enrollment target

Study Summary

Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2014-10
Est. Completion 2018-08

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT02276170

The ClinicalTrials.gov registry entry for NCT02276170 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02276170 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02276170 about?

NCT02276170 is a clinical study titled "Pharmacology of Aminophylline for Acute Kidney Injury in Neonates". Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project wil...

What is the current status of trial NCT02276170?

This trial is currently terminated. The enrollment target is 9 participants. The study started on 2014-10. Estimated completion is 2018-08.

Who is sponsoring clinical trial NCT02276170?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.